Introduction {#Sec1}
============

The involvement of calcitonin gene-related peptide (CGRP) in migraine pathophysiological mechanisms is convincingly shown by the facts that CGRP can induce migraine \[[@CR1]\] and that two CGRP antagonists, olcegepant \[[@CR2]\] and telcagepant \[[@CR3], [@CR4]\], are effective in the treatment of migraine attacks.

CGRP is a 37-amino-acid neuropeptide, first identified in 1982 \[[@CR5]\]. CGRP belongs to a family of peptides which includes calcitonin, adrenomedullin and amylin. There is a wide distribution of CGRP immunoreactive structures in the peripheral nervous system and in the CNS \[[@CR6], [@CR7], [@CR8]\]. CGRP-containing nerves innervate blood vessels in various regions of the body and the neuropeptide is a potent vasodilator. The physiological role of CGRP in the cardiovascular system is still not well understood \[[@CR6]\]. In the cerebral circulation there is a dense supply of CGRP-containing nerve fibres which originate in the trigeminal ganglion \[[@CR8], [@CR9], [@CR10]\] and the most pronounced action of CGRP is that of intracranial vasodilatation \[[@CR11]\]. In addition, CGRP is also involved in pain sensations \[[@CR12]--[@CR14]\]. For general reviews of CGRP, see \[[@CR15], [@CR16]\].

Until recently it has been an established fact that CGRP is increased in external jugular blood when measured during attacks of migraine \[[@CR17], [@CR18]\] and cluster headache \[[@CR19]--[@CR21]\]. In 2005 a study with intra-patient control found, however, no change when CGRP was measured in the EJV during and outside of migraine attacks without aura \[[@CR22]\]. This was the case with a new validated assay \[[@CR23]\] and also with the very same assay used previously \[[@CR17]--[@CR19]\]. It has been stated that "CGRP is released in prolonged, severe attacks of migraine" \[[@CR17], [@CR24]\], but the duration of attacks was similar in these two studies \[[@CR17], [@CR22]\] (see below). Thus, the discrepancy between these studies remains unresolved until now.

In the following the available studies shall be analysed in depth followed by a conclusion.

Animal studies {#Sec2}
==============

CGRP is involved in the transient arteriolar dilatation that is characteristic of cortical spreading depression (CSD) \[[@CR25], [@CR26]\]. One would therefore expect an increase of CGRP after CSD in the blood drained from the brain. This possibility was investigated in cats after CSD by sampling of blood for determination of CGRP from the EJV \[[@CR27]\]. Blood was sampled during passage of a wave of CSD and 60 min later. No increase of CGRP was found \[[@CR27]\]. It has been shown in cats that the internal carotid system is vestigial \[[@CR27], [@CR28]\]. Most of the cerebral blood flow thus passes through the rete mirabile and the extra-cranial venous circulation \[[@CR28]\]. It is therefore unlikely that the negative finding in this study could be attributed to the sampling in the EJV \[[@CR27]\]. CGRP does not readily cross the blood brain barrier (BBB) \[[@CR29], [@CR30]\] and it was suggested that, even if CSD cause release of CGRP locally, it did not cross the BBB into the venous circulation in significant concentrations \[[@CR27]\].

In contrast, trigeminal stimulation caused an increase (22--26%) of CGRP in the EJV in cats in two studies \[[@CR18], [@CR31]\]. In one study there was 66% increase in substance P \[[@CR31]\], whereas substance P was not measured in the other study \[[@CR18]\]. The effect on CGRP levels could in one study be antagonized by administration of either sumatriptan or dihydroergotamine \[[@CR18]\]. The effect of trigeminal stimulation is an increase in cerebral blood flow in cats \[[@CR18], [@CR32]\] and this increase could be reduced with sumatriptan and dihydroergotamine \[[@CR18]\]. In contrast, electrical stimulation of the trigeminal ganglion in monkeys resulted in a frequency-dependent decrease in external carotid resistance but had no effect on bulk flow and resistance in the internal carotid circulation \[[@CR33]\]. Trigeminal ganglion stimulation in rats caused an increase of facial skin blood flow and this increase was inhibited by a CGRP antagonist \[[@CR34]\]. Stimulation of trigeminal ganglion caused an increase of CGRP in jugular vein and this increase could be blocked by sumatriptan \[[@CR35]\]. Stimulation of superior sagittal sinus in cats caused an 85% rise in CGRP in the EJV and a 300% rise in VIP, but no increase in substance P \[[@CR36]\]. The increase of CGRP levels could be inhibited by avitriptan \[[@CR37]\].

The animal studies thus indicate that CGRP is increased in the EJV if there is a 'nervous vasodilatory drive'. Due to the vestigial cephalic circulation of animals (see above), it is not possible to establish whether the observed increase of CGRP in EJV is the result of an intracranial or extracranial release of CGRP.

In one rat study, nitroglycerin (NTG) in doses of 2 and 50 μg/kg per min failed to change CGRP levels in the jugular vein indicating that NTG exerts its migraine- or cluster headache-inducing effect without involving this neuropeptide \[[@CR38]\].

Studies on external jugular venous blood in cluster headache {#Sec3}
============================================================

For studies in which CGRP levels were measured in the EJV during cluster headache attacks, see Table [1](#Tab1){ref-type="table"}. In total 42 cluster headache attacks were investigated. Thirteen of these attacks were spontaneous attacks \[[@CR19]\] and 29 were induced by sublingual nitroglycerin (NTG) \[[@CR19], [@CR20]\]. In the spontaneous attacks an increase in CGRP (mean 110 ± 7 pmol/l) in the EJV was found compared to controls (41 ± 6 pmol/l) and there was a normalization of CGRP levels to 38 ± 6 pmol/l after either subcutaneous sumatriptan 6 mg or O~2~ inhalation \[[@CR19]\] (Table [1](#Tab1){ref-type="table"}). In the patients treated with pethidine there was no similar decrease in CGRP \[[@CR19]\]. In the other studies \[[@CR20], [@CR21]\] the baseline values before administration of NTG were determined. In both studies CGRP was more than doubled during the cluster headache attacks and spontaneous resolution of attacks or resolution after sumatriptan normalised the CGRP levels in EJV (Table [1](#Tab1){ref-type="table"}) \[[@CR20], [@CR21]\]. The most extensive study \[[@CR21]\] is illustrated in Fig. [1](#Fig1){ref-type="fig"}. It can be seen that vasodilator NTG per se did not increase the CGRP levels. Also at the beginning of the cluster headache attack there was no increase but after 1 h there was a doubling of the CGRP levels, and subcutaneous sumatriptan 6 mg resulted in resolution of attacks and normalization of CGRP levels \[[@CR21]\].Table 1Overview of CGRP levels (pmol/l) in external jugular vein during cluster headache \[[@CR15]--[@CR17]\]Cluster headache attacksDuring attacks pmol/lAfter treatment (after spontaneous resolution or outside attack)Thirteen patients with spontaneous cluster headache attacks \[[@CR19]\]110 ± 738 ±[ ]{.ul}6^a^Controls41 ± 6Twelve NTG induced cluster headache attacks \[[@CR20]\]46 ± 3\
Baseline^b^: 20 ± 222 ± 2 (after spontaneous resolution)Six NTG induced cluster headache attacks \[[@CR20]\]50 ± 4\
Baseline^b^: 18 ± 222 ± 2^c^NTG induced cluster headache in 11 patients \[[@CR21]\]52 ± 7\
Baseline^b^: 19 ± 222 ± 2^c^Results are given the mean ± SE^a^Treatment with either subcutaneous sumatriptan 6 mg or O~2~^b^Baseline before sublingual nitroglycerin 0.9 mg^c^Treatment with subcutaneous sumatriptan 6 mgFig. 1CGRP levels (pmol/l) in external julular vein during nitroglycerin (NTG)-induced cluster headache. Note that NTG per se did not increase CGRP. At the start of the cluster headache attacks there was no increase in CGRP. At the maximum of attack CGRP increased twofold. Sumatriptan caused a normalization of CGRP levels, redrawn from \[[@CR21]\]

Thus, in contrast to migraine (see below), there is no doubt that CGRP is increased in EJV in cluster headache. In the three studies there is both an approximately twofold increase in CGRP during attacks and a normalization of CGRP occurred after spontaneous resolution or treatment with either sumatriptan or O~2~ \[[@CR19]--[@CR21]\].

Studies on external jugular venous blood in migraine {#Sec4}
====================================================

An overview of studies in which CGRP levels were measured in the EJV during migraine is given Table [2](#Tab2){ref-type="table"}. In two studies, (*n* = 22) \[[@CR17]\] and (*n* = 8) \[[@CR18]\], from the Australian and Swedish group by Goadsby and Edvinsson there were increased levels of CGRP during migraine attacks (Table [2](#Tab2){ref-type="table"}). During attacks CGRP decreased in seven out of eight patients responding to sumatriptan treatment \[[@CR18]\] (Fig. [2](#Fig2){ref-type="fig"}). In contrast, in the Danish study (*n* = 17) with intra-patient comparison there was not even a tendency for an increase during migraine attack of migraine without aura (Table [2](#Tab2){ref-type="table"}) \[[@CR22]\]. This was the case where whether CGRP was measured with the same radioimmunoassay as used previously by Goadsby and Edvinsson \[[@CR17], [@CR18]\] or another sensitive assay \[[@CR23]\]. There was an excellent intrapatient consistency between levels in EJV blood and cubital blood during migraine attacks with both assays indicating that no CGRP was released from the extracranial tissue \[[@CR22]\].Table 2Overview of CGRP levels (pmol/l) in external jugular vein during and outside migraine attacks \[[@CR13], [@CR14], [@CR18]\]Migraine attacksDuring attacks pmol/lAfter treatment (after spontaneous resolution or outside attack)Ten migraine with aura (MA) \[[@CR17]\]92 ± 11Twelve migraine without aura (MO) \[[@CR17]\]86 ± 4Controls\<40Two MA and six MO \[[@CR18]\]60 ± 840 ± 8^a^Seventeen MO patients \[[@CR22]\] Assay I17 (range \<10--42)16 (range \<10--28) (outside attacks) Assay II33 (range 5--57)31 (range 14--61)Results are given the mean ± SE^a^Treatment with subcutaneous sumatriptan 6 mgFig. 2Effect of subcutaneous sumatriptan 6 mg on CGRP levels (pmol/l) in external jugular vein during migraine attacks (*n* = 8). Seven of eight patients responded to sumatriptan and in all these cases a decrease in CGRP levels was observed. One patient did not respond and there was no change in CGRP levels in this patient \[[@CR18]\]

These different findings in the EJV \[[@CR17], [@CR18], [@CR22]\] are very difficult to reconcile. Are there differences in the patient populations? In the first two 'positive' studies a mixture of migraine with and without aura was investigated \[[@CR17], [@CR18]\], whereas in the 'negative' study only migraine without aura patients was studied \[[@CR22]\]. In the first study the increased blood levels of CGRP was, however, similar during migraine with aura (92 pmol/l, *n* = 10) and migraine without aura (86 pmol/l, *n* = 12) \[[@CR17]\]. The controls levels were \<40 pmol/l. The controls were 12 healthy females aged between 19 and 25 years \[[@CR17]\]. The mean age in the migraine patients was 36 years (range 22--58 years) in the migraine patients \[[@CR17]\] which was roughly similar to the patients in the Danish study: mean age 39 years, range 26--53 years \[[@CR22]\]. The female/male sex ratios were 16/6 \[[@CR17]\] and 17/4 \[[@CR22]\], respectively. The influence of sex and age was studied in one large study with cubital blood in 223 normal individuals and serum levels of CGRP (mean 36 pmol/l) were unrelated to sex and age \[[@CR23]\].

It has recently been stated \[[@CR24]\] that "CGRP is released in prolonged, severe attacks of migraine" with a reference to \[[@CR17]\]. The duration of the actual studied attacks were, however, similar in two of the studies \[[@CR17], [@CR22]\] with either 'positive' or 'negative' results, both median 3 h, range 1--7 h \[[@CR17]\] and mean 201 min, range 95--305 min \[[@CR22]\] whereas in the third study the median was 11 h and the range was $\documentclass[12pt]{minimal}
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                \begin{document}$$1\frac{1}{2}\,{\text{h}}\,{\text{to}}\,3\frac{1}{2}\,{\text{weeks (sic)}}$$\end{document}$ \[[@CR18]\]. The severity of headache in these three studies cannot be compared because in two of the studies with 'positive' results there are no data on headache severity \[[@CR17], [@CR18]\]. In the study with intrapatient comparison, in which all patients fulfilled the diagnostic criteria for migraine without aura \[[@CR39]\], the headache was severe in seven, moderate in 13 and mild in one patient \[[@CR22]\]. The headache was unilateral in 19 patients \[[@CR22]\]. There was no correlation between CGRP levels and severity and duration of attacks \[[@CR22]\]. In the second 'positive' study (*n* = 8) no controls were used but CGRP levels before (mean 60 pmol/l) and after subcutaneous sumatriptan (mean 40 pmol/l) (*P* = 0.016, Sign test) were measured \[[@CR18]\] (Fig. [2](#Fig2){ref-type="fig"}). It has been argued that the decrease in CGRP levels after sumatriptan could be an effect of the drug per se and not related to the anti-migraine effect of sumatriptan \[[@CR22]\]. The argument was based on an in vitro study, showing depression of CGRP in trigeminal cells by sumatriptan \[[@CR40]\], but in human volunteers subcutaneous sumatriptan was without any effect on CGRP levels in the EJV \[[@CR41]\]. The effect of sumatriptan on CGRP is thus most likely caused by an anti-migraine effect.

Thus, for migraine there is some uncertainty as to whether CGRP is increased in the EJV in all migraine patients. There are two 'positive' studies \[[@CR17], [@CR18]\], finding increased CGRP during migraine attacks, whereas the study with the best methodology, the intra-patient comparison, did not find even an indication of an increase in CGRP \[[@CR22]\]. More studies are needed in order to settle the question of whether CGRP is increased in migraine.

One should not just repeat previous studies but go for the optimum design. This was used in one of the cluster headache studies \[[@CR21]\]. CGRP was measured before, after provocation with NTG, at the beginning of attack, at the maximum of attack and after the attack was resolved \[[@CR21]\]. Such a design used in migraine with i.v. NTG provocation of attacks \[[@CR42], [@CR43]\] is somewhat cumbersome, but since NTG triggers genuine migraine attacks \[[@CR42], [@CR43]\] it would once and for all settle the question of whether CGRP is increased in EJV during migraine attacks.

Other studies with CGRP in cubital blood and internal jugular blood {#Sec5}
===================================================================

In two of the studies mentioned earlier \[[@CR17], [@CR22]\], no increase in CGRP in the cubital blood during migraine attacks was observed, whereas Gallai et al. found an increase of CGRP in 30 young, migraine-with-aura patients and 45 young, migraine-without-aura patients when studied during (mean 56 + 7 pmol l) and outside attacks (mean 39 ± 9 pmol l) \[[@CR41]\]. Since there are no indications that younger migraine patients have a different migraine pathophysiology than adults, the 'positive' study \[[@CR44]\] remains unexplained for it is difficult to understand how an increase in CGRP in EJV (blood flow 160 ml/min) could be picked up in the systemic circulation (minute volume 5,000 ml/min). Similarly, no increase of CCGRP could be detected (detection limit 20 pmol/l) \[[@CR45]\] in the cubital vein during trigeminal thermocoagulation \[[@CR46]\].

In nitroglycerin-induced migraine attacks there was a minor but significant increase (6 pmol/l) of CGRP level in cubital blood in one study \[[@CR47]\] and there was a correlation between plasma levels of CGRP and severity of migraine \[[@CR47]\]. In another study using nitroglycerin provocation migraine patients, that responded to intranasal sumatriptan 20 mg had a minor (17--15 pmol/l, *n* = 6) decrease in CGRP level in cubital blood after sumatriptan, whereas this was not the case for non-responders (24--24 pmol/l, *n* = 13) \[[@CR48]\].

In one study CGRP levels in a cubital vein was unchanged after 10, 20 and 60 min nitroglycerin infusion \[[@CR49]\].

In one small Italian study (*n* = 5) of CGRP in the internal jugular venous blood was found increased with a maximum after 1 h during repeated measurement up to 6 and 2 h after the migraine without aura attacks which were spontaneous and untreated \[[@CR50]\]. In contrast, this was not the case in a small Danish study (*n* = 4) of CGRP in internal jugular venous blood studied during migraine aura \[[@CR51]\]. The arterial CGRP levels were in all cases (*n* = 8) greater than the control value of \<40 pmol/l \[[@CR51]\].

The specificity of the CGRP for primary headaches was demonstrated in one study of cervicogenic headache in which samples were taken from EJV and anticubital vein \[[@CR52]\]. No difference was found between CGRP levels assessed on days with and without headache in neither of these veins \[[@CR52]\].

Which tissues does the EJV drain? {#Sec6}
=================================

The bulk of EJV blood flow comes from the extracranial tissue of head and face. In addition, the middle meningeal veins go through the foramen spinosum drain into the pterygoidal plexus \[[@CR53]\] and this is a tributary to the EJV. The blood flow in the meningeal veins is likely to be comparable to blood flow in middle meningeal artery (MMA) Blood flow in the MMA in man is unknown. According to Fig. 940 in Spalteholz \[[@CR53]\] the MMA is only a minor ramification of the external carotid artery. It is even smaller than the superficial temporal artery. Based on this indirect estimation blood flow in the middle meningeal veins contributes only to a small fraction of to blood in the EJV.

It is generally not known that 22% of the blood flow in the EJV comes from the cerebral circulation in man \[[@CR54]\]. The venous circulation of the brain has numerous, but small, communication with extracerebral pathways. These are the emissary veins of the skull and the veins passing through the foramens of the base of the skull and the orbit and the veins which communicate with the pterygoid plexus \[[@CR54]\]. Based on the possible increase of CGRP in internal jugular vein of an increase of 40 pmol/l found in one study \[[@CR50]\], and based on a 22% contribution of cerebral blood to the EJV blood flow, it can be estimated that the contribution of cerebral blood can theoretically increase CGRP levels in EJV with 8 pmol/l. This calculation presumes that the analyses of CGRP are comparable, which is not the case (see Table [1](#Tab1){ref-type="table"}). Anyway, this theoretical calculation indicates that only a smaller part of CGRP in EJV during cluster headache and possibly migraine is likely to come from the cerebral circulation (see Table [1](#Tab1){ref-type="table"}).

In addition, the lack of increase in CGRP in EJV blood after CSD in cats \[[@CR27]\] would indicate that the increased CGRP levels in the EJV during migraine with aura \[[@CR17]\], in which CSD is the most likely the primary putative event \[[@CR55], [@CR56]\], is not derived from the brain. The CGRP in blood in EJV is thus most likely derived from part of the vasculature without BBB.

Other relevant studies in man {#Sec7}
=============================

In this section, I will review some studies on arterial and blood flow changes relevant to a possible increase in CGRP in the EJV during migraine attacks and a certain increase during cluster headache attacks.

During 25 migraine attacks the temporal artery, as measured with ultrasound, during and outside attacks, on the symptomatic was not constricted whereas this was the case for the temporal artery on the non-symptomatic side \[[@CR57]\]. In addition, the radial arteries were constricted during migraine attacks \[[@CR57]\]. This indicates a general vasoconstrictory effect during the migraine attack \[[@CR57]\]. Similarly, the temporal artery on the symptomatic side in cluster headache attacks (*n* = 9) was not constricted whereas this was the case on the non-symptomatic \[[@CR58]\]. This indicates that there is an extracranial "vasodilatory drive" present on the symptomatic side during migraine and cluster headache \[[@CR57], [@CR58]\].

Only patients (*n* = 6) with facial flushing during trigeminal thermocoagulation showed an increase in CGRP in the EJV \[[@CR31]\] whereas the patients (*n* = 3) without flushing showed no change. This supports the hypothesis that a "nervous vasodilatory drive" is necessary for release of CGRP from the extracranial vasculare bed. Thermographic studies have shown that facial flushing after thermocoagulation of Gasserian ganglion can be shown to be associated with increased skin temperature \[[@CR59]\]. In cluster headache heat loss was increased from the affected orbital region. O~2~ treatment, which was effective in 22 of 25 patients, caused the asymmetry of heat loss to disappear \[[@CR60]\]. Also in half-sided migraine attacks the ipsilateral-side had greater heat loss than the contralateral asymptomatic side \[[@CR61]\].

That CGRP can be involved in flushing was also shown in a double-blind study in which intravenous administered human α-CGRP 2 μg/kg per min caused flushing in the head and upper part of the body \[[@CR62]\] whereas this was not the case after placebo. The flushing can be inhibited by the CGRP antagonist BIBN4096BS (olcegepant) \[[@CR62]\] which also inhibited headache and extracranial vasodilatation \[[@CR62]\].

Conclusion {#Sec8}
==========

Im migraine there are two 'postive' studies \[[@CR17], [@CR18]\] demonstrating increased CGRP levels in EJV during attacks whereas a negative study, using intra-patient comparison, found no change in CGRP in EJV \[[@CR22]\]. For migraine there is thus some uncertainty as to whether CGRP in EJV is increased in all migraine patients; and more research, preferably with the intra-patient design with repeated measurements after provocation with NTG \[[@CR21]\] (see above), is recommended.

For cluster headache there are three studies, one in spontaneous attacks \[[@CR19]\] and two in nitroglycerin induced attacks \[[@CR20], [@CR21]\], which showed an increase in CGRP levels in EJV with normalisation after sumatriptan, O~2~ inhalation or spontaneous resolution.

The bulk of the blood in the EJV comes from the extracranial tissue and the face; only onefifth comes from the cerebral circulation \[[@CR54]\]. Thus, changes in CGRP found in the EJV most likely reflect what is going on in this extracranial tissue that it drains. It has been shown with ultrasound that the temporal artery on the symptomatic headache is not constricted during migraine or cluster headache attacks whereas the artery is constricted on the contralateral side \[[@CR57], [@CR58]\]. These findings indicate that there is a 'vasodilator drive' on the symptomatic side counteracting a vasonstriction and at the same time releasing CGRP from nerves in this vascular bed.

How this fits into the migraine inducing effect of CGRP \[[@CR1]\] and the efficacy of CGRP-antagonists in migraine \[[@CR2]--[@CR4]\] remains unclear. The issue whether increased CGRP in EJV, if present, is more than a 'marker for the trigeminovascular system remains to be investigated.

None.
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